

DOAC Filter



Specific filtration of DOAC in plasma

Easy to use
No residue in eluted plasma
Reliable results




Stago

Specific filtration of DOAC in plasma

DOAC (Direct Oral Anticoagulant) are removed from citrated plasma thanks to a filtration technique on chemical phase.

- Rivaroxaban
- Apixaban
- Edoxaban
- Dabigatran

- ✓ Retention of DOAC up to 300 ng/mL
- ✓ Residual concentration : see table below
- ✓ No residue in eluted plasma
- ✓ Easy to use
- ✓ Reliable results



Residual concentrations of DOAC and plasmas volume following filtration

Results obtained after filtration of 600 µL of a normal plasma spiked with 300 ng/mL of each DOAC :

Average residual DOAC concentration on eluted plasma, assessed with LCMS method						DOAC Filter Cat. Nr 01345 20 cartridges per box
	Eluted plasma volume	Rivaroxaban	Apixaban	Edoxaban	Dabigatran	
n	70 cartridges	20 cartridges	20 cartridges	20 cartridges	20 cartridges	
Average	485 µL (455 to 505 µL)	< 5 ng/mL	13 ng/mL (9 to 32 ng/mL)	< 5 ng/mL	< 5 ng/mL	

Bibliography

Carlo A, Landou C, Morange PE, Suchon P, DOAC filter efficacy and interest in patients undergoing LA testing, ISTH 2019 Melbourne

Research Use Only

STA is trademark of the Stago Group. The rights of the trademarks and logos used in this document belong to the Stago Group. The use of these trademarks is not permitted without permission from the Stago Group.

For further information, please contact:



Diagnostica Stago S.A.S.
3 allée Thérèse
92600 Asnières sur Seine - France
Tel.: +33 1 46 88 20 20
Fax: +33 1 47 91 08 91
webmaster@stago.com
www.stago.com